Download PDF
Thromb Haemost 2021; 121(04): 433-448
DOI: 10.1055/s-0040-1718414
Coagulation and Fibrinolysis

Chemical Modulators of Fibrinogen Production and Their Impact on Venous Thrombosis

Rui Vilar
1   Department of Genetic Medicine and Development, University of Geneva Faculty of Medicine, Geneva, Switzerland
,
Samuel W. Lukowski
1   Department of Genetic Medicine and Development, University of Geneva Faculty of Medicine, Geneva, Switzerland
2   Institute for Molecular Bioscience, The University of Queensland, Saint Lucia, Queensland, Australia
,
Marco Garieri
1   Department of Genetic Medicine and Development, University of Geneva Faculty of Medicine, Geneva, Switzerland
,
Corinne Di Sanza
1   Department of Genetic Medicine and Development, University of Geneva Faculty of Medicine, Geneva, Switzerland
,
Marguerite Neerman-Arbez
1   Department of Genetic Medicine and Development, University of Geneva Faculty of Medicine, Geneva, Switzerland
3   iGE3, Institute of Genetics and Genomics in Geneva, Geneva, Switzerland
,
Richard J. Fish
1   Department of Genetic Medicine and Development, University of Geneva Faculty of Medicine, Geneva, Switzerland
› Author Affiliations Funding This study was supported by a Swiss National Science Foundation grant (#31003A_152633) to M. Neerman-Arbez and a Novartis Foundation for Medical-Biological Research grant to R.J. Fish. We thank the University of Geneva Faculty of Medicine Proteomics, Flow Cytometry and Bioimaging services for their technical assistance and advice.
› Further Information
Also available at
   Permissions and Reprints

Abstract

Thrombosis is a leading cause of morbidity and mortality. Fibrinogen, the soluble substrate for fibrin-based clotting, has a central role in haemostasis and thrombosis and its plasma concentration correlates with cardiovascular disease event risk and a prothrombotic state in experimental models. We aimed to identify chemical entities capable of changing fibrinogen production and test their impact on experimental thrombosis. A total of 1,280 bioactive compounds were screened for their ability to alter fibrinogen production by hepatocyte-derived cancer cells and a selected panel was tested in zebrafish larvae. Anthralin and all-trans retinoic acid (RA) were identified as fibrinogen-lowering and fibrinogen-increasing moieties, respectively. In zebrafish larvae, anthralin prolonged laser-induced venous- occlusion times and reduced thrombocyte accumulation at injury sites. RA had opposite effects. Treatment with RA, a nuclear receptor ligand, increased fibrinogen mRNA levels. Using an antisense morpholino oligonucleotide to deplete zebrafish fibrinogen, we correlated a shortening of laser-induced venous thrombosis times with RA treatment and fibrinogen protein levels. Anthralin had little effect on fibrinogen mRNA in zebrafish larvae, despite leading to lower detectable fibrinogen. Therefore, we made a proteomic scan of anthralin-treated cells and larvae. A reduced representation of proteins linked to the canonical secretory pathway was detected, suggesting that anthralin affects protein secretion. In summary, we found that chemical modulation of fibrinogen levels correlates with measured effects on experimental venous thrombosis and could be investigated as a therapeutic avenue for thrombosis prevention.

Keywords

all-trans retinoic acid - anthralin - fibrinogen - thrombosis - zebrafish

Supplementary Material



Publication History

Received: 08 May 2020

Accepted: 02 September 2020

Article published online:
10 December 2020

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

Comment to this article:

Small Molecules: A Novel Approach to Alter Fibrinogen Production and Impact Venous ThrombosisThromb Haemost 2021; 121(04): 408-408
DOI: 10.1055/s-0040-1721318

 

  • References

  • 1 Raskob GE, Angchaisuksiri P, Blanco AN. et al; ISTH Steering Committee for World Thrombosis Day. Thrombosis: a major contributor to global disease burden. Arterioscler Thromb Vasc Biol 2014; 34 (11) 2363-2371
    CrossrefPubMedGoogle Scholar
  • 2 Wendelboe AM, McCumber M, Hylek EM, Buller H, Weitz JI, Raskob G. ISTH Steering Committee for World Thrombosis Day. Global public awareness of venous thromboembolism. J Thromb Haemost 2015; 13 (08) 1365-1371
    CrossrefPubMedGoogle Scholar
  • 3 Lozano R, Naghavi M, Foreman K. et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380 (9859): 2095-2128
    CrossrefPubMedGoogle Scholar
  • 4 Coleman CI, Sobieraj DM, Winkler S. et al. Effect of pharmacological therapies for stroke prevention on major gastrointestinal bleeding in patients with atrial fibrillation. Int J Clin Pract 2012; 66 (01) 53-63
    CrossrefPubMedGoogle Scholar
  • 5 Ahrens I, Lip GY, Peter K. New oral anticoagulant drugs in cardiovascular disease. Thromb Haemost 2010; 104 (01) 49-60
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 (6, Suppl): 160S-198S
    CrossrefPubMedGoogle Scholar
  • 7 Berger JS, Krantz MJ, Kittelson JM, Hiatt WR. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials. JAMA 2009; 301 (18) 1909-1919
    CrossrefPubMedGoogle Scholar
  • 8 Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2, Suppl): e44S-e88S
    CrossrefPubMedGoogle Scholar
  • 9 Weitz JI, Eikelboom JW, Samama MM. New antithrombotic drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2, Suppl): e120S-e151S
    CrossrefPubMedGoogle Scholar
  • 10 Jagadeeswaran P, Cooley BC, Gross PL, Mackman N. Animal models of thrombosis from zebrafish to nonhuman primates: use in the elucidation of new pathologic pathways and the development of antithrombotic drugs. Circ Res 2016; 118 (09) 1363-1379
    CrossrefPubMedGoogle Scholar
  • 11 Weisel JW, Litvinov RI. Fibrin formation, structure and properties. Subcell Biochem 2017; 82: 405-456
    CrossrefPubMedGoogle Scholar
  • 12 Mosesson MW, Siebenlist KR, Meh DA. The structure and biological features of fibrinogen and fibrin. Ann N Y Acad Sci 2001; 936: 11-30
    CrossrefPubMedGoogle Scholar
  • 13 Kant JA, Fornace Jr AJ, Saxe D, Simon MI, McBride OW, Crabtree GR. Evolution and organization of the fibrinogen locus on chromosome 4: gene duplication accompanied by transposition and inversion. Proc Natl Acad Sci U S A 1985; 82 (08) 2344-2348
    CrossrefPubMedGoogle Scholar
  • 14 Espitia Jaimes C, Fish RJ, Neerman-Arbez M. Local chromatin interactions contribute to expression of the fibrinogen gene cluster. J Thromb Haemost 2018; 16 (10) 2070-2082
    CrossrefPubMedGoogle Scholar
  • 15 Danesh J, Lewington S, Thompson SG. et al; Fibrinogen Studies Collaboration. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA 2005; 294 (14) 1799-1809
    PubMedGoogle Scholar
  • 16 Zhang Y, Zhu C-G, Guo Y-L. et al. Higher fibrinogen level is independently linked with the presence and severity of new-onset coronary atherosclerosis among Han Chinese population. PLoS One 2014; 9 (11) e113460
    CrossrefPubMedGoogle Scholar
  • 17 Machlus KR, Cardenas JC, Church FC, Wolberg AS. Causal relationship between hyperfibrinogenemia, thrombosis, and resistance to thrombolysis in mice. Blood 2011; 117 (18) 4953-4963
    CrossrefPubMedGoogle Scholar
  • 18 Suh TT, Holmbäck K, Jensen NJ. et al. Resolution of spontaneous bleeding events but failure of pregnancy in fibrinogen-deficient mice. Genes Dev 1995; 9 (16) 2020-2033
    CrossrefPubMedGoogle Scholar
  • 19 Fish RJ, Di Sanza C, Neerman-Arbez M. Targeted mutation of zebrafish fga models human congenital afibrinogenemia. Blood 2014; 123 (14) 2278-2281
    CrossrefPubMedGoogle Scholar
  • 20 Hu Z, Lavik KI, Liu Y. et al. Loss of fibrinogen in zebrafish results in an asymptomatic embryonic hemostatic defect and synthetic lethality with thrombocytopenia. J Thromb Haemost 2019; 17 (04) 607-617
    CrossrefPubMedGoogle Scholar
  • 21 Vilar R, Fish RJ, Casini A, Neerman-Arbez M. Fibrin(ogen) in human disease: both friend and foe. Haematologica 2020; 105 (02) 284-296
    CrossrefPubMedGoogle Scholar
  • 22 Perisanidis C, Psyrri A, Cohen EE. et al. Prognostic role of pretreatment plasma fibrinogen in patients with solid tumors: a systematic review and meta-analysis. Cancer Treat Rev 2015; 41 (10) 960-970
    CrossrefPubMedGoogle Scholar
  • 23 Berger MD, Heini AD, Seipel K, Mueller B, Angelillo-Scherrer A, Pabst T. Increased fibrinogen levels at diagnosis are associated with adverse outcome in patients with acute myeloid leukemia. Hematol Oncol 2017; 35 (04) 789-796
    CrossrefPubMedGoogle Scholar
  • 24 Pedersen A, Stanne TM, Redfors P. et al. Fibrinogen concentrations predict long-term cognitive outcome in young ischemic stroke patients. Res Pract Thromb Haemost 2018; 2 (02) 339-346
    CrossrefPubMedGoogle Scholar
  • 25 Zhang Y, Zhang X, Liu D. et al. Elevated fibrinogen levels in neuromyelitis optica is associated with severity of disease. Neurol Sci 2016; 37 (11) 1823-1829
    CrossrefPubMedGoogle Scholar
  • 26 Fort A, Borel C, Migliavacca E, Antonarakis SE, Fish RJ, Neerman-Arbez M. Regulation of fibrinogen production by microRNAs. Blood 2010; 116 (14) 2608-2615
    CrossrefPubMedGoogle Scholar
  • 27 Keserü GM, Makara GM. The influence of lead discovery strategies on the properties of drug candidates. Nat Rev Drug Discov 2009; 8 (03) 203-212
    CrossrefPubMedGoogle Scholar
  • 28 Fish RJ, Vorjohann S, Béna F, Fort A, Neerman-Arbez M. Developmental expression and organisation of fibrinogen genes in the zebrafish. Thromb Haemost 2012; 107 (01) 158-166
    Article in Thieme ConnectPubMedGoogle Scholar
  • 29 Huang W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009; 4 (01) 44-57
    CrossrefPubMedGoogle Scholar
  • 30 Huang W, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 2009; 37 (01) 1-13
    CrossrefPubMedGoogle Scholar
  • 31 Jung M-L, Contreras J-M, Morice C, Simon J-M, Didier B, Langer T. The Prestwick Chemical Library®: a valuable tool for screening. Available at: http://www.prestwickchemical.com/pdf/2018-pcl-a-valuable-tool.pdf. Accessed March 30, 2020
    PubMedGoogle Scholar
  • 32 Havercroft JC, Quinlan RA, Gull K. Binding of parbendazole to tubulin and its influence on microtubules in tissue-culture cells as revealed by immunofluorescence microscopy. J Cell Sci 1981; 49: 195-204
    CrossrefPubMedGoogle Scholar
  • 33 Vasquez RJ, Howell B, Yvon AM, Wadsworth P, Cassimeris L. Nanomolar concentrations of nocodazole alter microtubule dynamic instability in vivo and in vitro. Mol Biol Cell 1997; 8 (06) 973-985
    CrossrefPubMedGoogle Scholar
  • 34 Giannattasio C, Cattaneo BM, Seravalle G. et al. Alpha 1-blocking properties of carvedilol during acute and chronic administration. J Cardiovasc Pharmacol 1992; 19 (Suppl. 01) S18-S22
    CrossrefPubMedGoogle Scholar
  • 35 Chekman IS. Experimental studies of the mechanism of action of reserpine [in Russian]. Biull Eksp Biol Med 1972; 73 (03) 59-61
    CrossrefPubMedGoogle Scholar
  • 36 Nicodeme E, Nicaud M, Issandou M. Retinoids stimulate fibrinogen production both in vitro (hepatocytes) and in vivo. Induction requires activation of the retinoid X receptor. Arterioscler Thromb Vasc Biol 1995; 15 (10) 1660-1667
    CrossrefPubMedGoogle Scholar
  • 37 Lin H-F, Traver D, Zhu H. et al. Analysis of thrombocyte development in CD41-GFP transgenic zebrafish. Blood 2005; 106 (12) 3803-3810
    CrossrefPubMedGoogle Scholar
  • 38 Yamashita R, Fujiwara Y, Ikari K. et al. Extracellular proteome of human hepatoma cell, HepG2 analyzed using two-dimensional liquid chromatography coupled with tandem mass spectrometry. Mol Cell Biochem 2007; 298 (1–2): 83-92
    CrossrefPubMedGoogle Scholar
  • 39 Dally N, Hoffman R, Haddad N, Sarig G, Rowe JM, Brenner B. Predictive factors of bleeding and thrombosis during induction therapy in acute promyelocytic leukemia-a single center experience in 34 patients. Thromb Res 2005; 116 (02) 109-114
    CrossrefPubMedGoogle Scholar
  • 40 Falanga A, Iacoviello L, Evangelista V. et al. Loss of blast cell procoagulant activity and improvement of hemostatic variables in patients with acute promyelocytic leukemia administered all-trans-retinoic acid. Blood 1995; 86 (03) 1072-1081
    CrossrefPubMedGoogle Scholar
  • 41 Torromeo C, Latagliata R, Avvisati G, Petti MC, Mandelli F. Intraventricular thrombosis during all-trans retinoic acid treatment in acute promyelocytic leukemia. Leukemia 2001; 15 (08) 1311-1313
    CrossrefPubMedGoogle Scholar
  • 42 Escudier SM, Kantarjian HM, Estey EH. Thrombosis in patients with acute promyelocytic leukemia treated with and without all-trans retinoic acid. Leuk Lymphoma 1996; 20 (5–6): 435-439
    CrossrefPubMedGoogle Scholar
  • 43 Losada R, Espinosa E, Hernández C, Dorticos E, Hernández P. Thrombocytosis in patients with acute promyelocytic leukaemia during all-trans retinoic acid treatment. Br J Haematol 1996; 95 (04) 704-705
    CrossrefPubMedGoogle Scholar
  • 44 Zhou B, Pan Y, Hu Z. et al. All-trans-retinoic acid ameliorated high fat diet-induced atherosclerosis in rabbits by inhibiting platelet activation and inflammation. J Biomed Biotechnol 2012; 2012: 259693
    CrossrefPubMedGoogle Scholar
  • 45 Luo Q, Wei G, Wang X. et al. All-trans retinoic acid impairs platelet function and thrombus formation and inhibits protein kinase CßI/δ phosphorylation. Thromb Haemost 2019; 119 (10) 1655-1664
    Article in Thieme ConnectPubMedGoogle Scholar
  • 46 Ashton RE, Andre P, Lowe NJ, Whitefield M. Anthralin: historical and current perspectives. J Am Acad Dermatol 1983; 9 (02) 173-192
    CrossrefPubMedGoogle Scholar
  • 47 Vanizor Kural B, Orem A, Cimşit G, Uydu HA, Yandi YE, Alver A. Plasma homocysteine and its relationships with atherothrombotic markers in psoriatic patients. Clin Chim Acta 2003; 332 (1–2): 23-30
    CrossrefPubMedGoogle Scholar
  • 48 Danik JS, Paré G, Chasman DI. et al. Novel loci, including those related to Crohn disease, psoriasis, and inflammation, identified in a genome-wide association study of fibrinogen in 17 686 women: the Women's Genome Health Study. Circ Cardiovasc Genet 2009; 2 (02) 134-141
    CrossrefPubMedGoogle Scholar
  • 49 Schopf RE, Weber H, Morsches B. Enhanced procoagulant activity of mononuclear leukocytes in patients with atopic dermatitis and psoriasis. Arch Dermatol Res 1993; 285 (05) 305-309
    CrossrefPubMedGoogle Scholar
  • 50 Le Fourn V, Park S, Jang I. et al. Large protein complexes retained in the ER are dislocated by non-COPII vesicles and degraded by selective autophagy. Cell Mol Life Sci 2013; 70 (11) 1985-2002
    CrossrefPubMedGoogle Scholar
  • 51 Pushpakom S, Iorio F, Eyers PA. et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov 2019; 18 (01) 41-58
    CrossrefPubMedGoogle Scholar